Arlington Capital Management Inc. Takes $985,000 Position in Novo Nordisk A/S (NYSE:NVO)

Arlington Capital Management Inc. purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 9,520 shares of the company's stock, valued at approximately $985,000.

A number of other large investors also recently bought and sold shares of the stock. Westside Investment Management Inc. grew its holdings in Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company's stock valued at $130,000 after buying an additional 649 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $2,408,000. Lazard Asset Management LLC grew its stake in shares of Novo Nordisk A/S by 182.2% in the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company's stock valued at $135,883,000 after buying an additional 964,640 shares during the period. CENTRAL TRUST Co increased its holdings in shares of Novo Nordisk A/S by 111.6% during the 3rd quarter. CENTRAL TRUST Co now owns 6,004 shares of the company's stock worth $546,000 after buying an additional 3,166 shares during the last quarter. Finally, Ieq Capital LLC raised its position in shares of Novo Nordisk A/S by 136.6% during the 3rd quarter. Ieq Capital LLC now owns 27,474 shares of the company's stock valued at $2,498,000 after buying an additional 15,860 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent analyst reports. UBS Group initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a "neutral" rating for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an "outperform" rating and a $163.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average target price of $133.60.

Novo Nordisk A/S Stock Up 1.5 %

Shares of NYSE NVO traded up $1.94 during midday trading on Thursday, hitting $128.63. The company's stock had a trading volume of 2,373,359 shares, compared to its average volume of 4,805,638. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The business's fifty day simple moving average is $127.43 and its two-hundred day simple moving average is $113.60. The firm has a market capitalization of $577.23 billion, a price-to-earnings ratio of 44.37, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.